Current therapeutic trends in therapy for chronic viral hepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 9-10, 1997, Pages

  Liaw, Yun Fan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chronic viral hepatitis; Corticosteroid hepatitis B virus; Hepatitis C virus; Hepatitis delta virus; Interferon

Indexed keywords

CORTICOSTEROID; FAMCICLOVIR; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; RECOMBINANT INTERFERON; RIBAVIRIN; THYMOSIN ALPHA1;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DRUG EFFICACY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK ASSESSMENT;

EID: 0030811412     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00520.x     Document Type: Conference Paper

References (45)

1. Chu CM, Shyu WC, Kuo RW, Liaw YF. HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: Its role in the pathogenesis of chronic type B hepatitis. Hepatology 1987; 7: 1311-16.
2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8: 493-6.
3. Liaw YF, Tai DI, Chu CM et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-7.
4. Liaw YF, Lee CS, Tsai SL et al. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368-70.
5. Sheen IS, Liaw YF, Lin DY, Chu CM. Acute exacerbation in chronic hepatitis C: A clinicopathological and prognostic study. J. Hepatol. 1996; 24: 525-31.
6. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang Chien CS. Clinical and histological events preceding hepatitis Be antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 216-19.
7. Liaw YF, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY. Determinants for hepatitis Be antigen clearance in chronic type B hepatitis. Liver 1984; 4: 301-6.
8. Liaw YF, Yang SS, Chen TJ et al. Acute exacerbation in hepatitis Be antigen positive chronic type B hepatitis: A clinicopathological study. J. Hepatol. 1985; 1: 227-33.
9. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993; 119: 312-23.
10. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-α in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology 1991; 13: 1052-6.
11. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1996; 22: 1101-8.
12. Hadziyannis SJ. Hepatitis Be antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev. 1995; 1: 7-36.
13. Hoofnagle JH, DiBisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-21.
14. Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titrable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
15. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo controlled trial of recombinant alpha-interferon in Chinese HBsAg carrier children. Lancet 1987; ii: 877-80.
16. Lai CL, Lin HJ, Lau JYN et al. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children. Q. J. Med. 1991; 78: 155-63.
17. Ruiz-Moreno M, Rua MJ, Molina J et al. Prospective, randomized controlled trial of interferon-α in children with chronic hepatitis B. Hepatology 1991; 13: 1035-9.
18. Liaw YF, Chien RN, Chen TJ, Sheen IS, Chu CM. Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis B virus infection. J. Med. Virol. 1992; 37: 294-7.
19. Fevery J, Elewaut A, Michielsen P et al. Efficacy of interferon α2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B: A prospective double-blind Belgian-Dutch study. J. Hepatol. 1990; 11: S108-12.
20. Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon α-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J. Hepatol. 1990; 11: S113-17.
21. Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Prospective randomized controlled trial of sequential treatment with corticoids and α-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur. J. Med. 1992; 1: 396-402.
22. Perrillo RP, Schiff ER, Davis GL et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 1990; 323: 295-301.
23. Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
24. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of predisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomized controlled trial. J. Hepatol. 1994; 20: 175-80.
25. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect meta-analysis. Hepatology 1994; 20: 1390-8.
26. Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: Incidence and risk factors. J. Gastroenterol. Hepatol. 1996; 11: 143-7.
27. Andreone P, Cursaro C, Gramenzi A et al. A randomized controlled trial of thymosin-α, versus interferon alfa in patients with hepatitis Be antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774-7.
28. Liaw YF, Chien RN, Sheen IS, Lai MY, Chen DS. A randomized, controlled, dose-ranging study of lamivudine in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 1995; 10: S68.
29. Dienstag JL, Perrillo RP, Schiff EF, Bartholomen M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
30. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24: S188.
31. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famiclovir in chronic hepatitis B: Results of a dose finding study. Hepatology 1996; 24: 188A.
32. Heathcote J, Mchutchison J, Benner K et al. Cy-1899: A therapeutic vaccine for chronic hepatitis B. Hepatology 1996; 24: S283.
33. Ponyard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 778-89.
34. Erickson AL, Houghton M, Chool QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J. Immunol. 1993; 151: 4189-99.
35. Koziel MJ, Dudley D, Afdhal N et al. Hepatitis C virus (HCV): Specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J. Virol. 1993; 67: 7522-32.
36. Liaw YF, Sheen IS, Lin SM et al. Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993; 13: 46-50.
37. Chayama K, Tsubota A, Kobayashi M et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology 1996; 23: 953-7.
38. Lai MY, Kao JH, Yang PM et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
39. Richard O, Nockrans G, Fivden A et al. Interferon-alpha and ribavirin versus interferon alpha alone as therapy for chronic hepatitis C: A randomized double-blind placebo controlled study. Hepatology 1996; 24: 356A.
40. Omata M, Takano S. A randomized controlled trial of interferon-β treatment for acute hepatitis C. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag, 1994; 601-3.
41. Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J. Gastroenterol. Hepatol. 1997; 12: 468-72.
42. Payen JL, Izopet J, Galindo V et al. A comparison of three interferon alfa-2b regimens for retreatment of patients with chronic hepatitis C with prior complete response followed by relapse: A controlled randomized trial. Hepatology 1996; 24: 273A.
43. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
44. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 1422-7.
45. Kuwana K, Ichida T, Kamimura T et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: A multivariate analysis in 343 patients. J. Gastroenterol. Hepatol. 1997; 12: 149-55.